How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,032 results for

Prevention of Kidney Disease Progression

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. (PubMed)

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Non-randomised data have shown a link between hyperuricaemia and the progression or development of chronic kidney disease (CKD). If this is correct, urate lowering therapy might form an important part of chronic kidney disease care, reducing risks for cardiovascular outcomes and end-stage kidney disease.This review aims to study the benefits and harms of uric acid lowering therapy (...) ).There is insufficient evidence to support an effect on blood pressure, proteinuria or other cardiovascular markers by uric acid lowering therapy. It should be noted that the apparent benefits of treatment were not apparent at all time points, introducing the potential for bias.There is limited data which suggests uric acid lowering therapy may prevent progression of chronic kidney disease but the conclusion is very uncertain. Benefits were not observed at all time points and study quality was generally low. Larger

Full Text available with Trip Pro

2017 Cochrane

2. Glucose targets for preventing diabetic kidney disease and its progression. (PubMed)

Glucose targets for preventing diabetic kidney disease and its progression. Diabetes is the leading cause of end-stage kidney disease (ESKD) around the world. Blood pressure lowering and glucose control are used to reduce diabetes-associated disability including kidney failure. However there is a lack of an overall evidence summary of the optimal target range for blood glucose control to prevent kidney failure.To evaluate the benefits and harms of intensive (HbA1c < 7% or fasting glucose levels (...) < 120 mg/dL versus standard glycaemic control (HbA1c ≥ 7% or fasting glucose levels ≥ 120 mg/dL for preventing the onset and progression of kidney disease among adults with diabetes.We searched the Cochrane Kidney and Transplant Specialised Register up to 31 March 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE

2017 Cochrane

3. Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain

Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain Article Text Commentary: General medicine Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain Clement Lo , Sophia Zoungas Statistics from Altmetric.com Commentary on: Ruospo M, Saglimbe VM, Palmer SC, et al . Glucose targets for preventing diabetic kidney disease and its progression

2017 Evidence-Based Medicine (Requires free registration)

4. Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Di (PubMed)

Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? : Editorial to: "Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Di

Full Text available with Trip Pro

2018 Cardiovascular Drugs and Therapy

5. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. (PubMed)

Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disorder causing kidney disease. Current clinical management of ADPKD focuses primarily on symptom control and reducing associated complications, particularly hypertension. In recent years, improved understanding of molecular and cellular mechanisms involved in kidney cyst growth and disease progression has resulted (...) in new pharmaceutical agents to target disease pathogenesis to prevent progressive disease.We aimed to evaluate the effects of interventions for preventing ADPKD progression on kidney function, kidney endpoints, kidney structure, patient-centred endpoints (such as cardiovascular events, sudden death, all-cause mortality, hospitalisations, BP control, quality of life, and kidney pain), as well as the general and specific adverse effects related to their use.We searched the Cochrane Renal Group's

Full Text available with Trip Pro

2015 Cochrane

6. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. (PubMed)

Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Early referral of patients with chronic kidney disease (CKD) is believed to help with interventions to address risk factors to slow down the rate of progression of kidney failure to end-stage kidney disease (ESKD) and the need for dialysis, hospitalisation and mortality.We sought to evaluate the benefits (reduced hospitalisation and mortality; increased quality of life) and harms (...) , heterogeneity in most of the analyses was high.Our analysis showed reduced mortality and mortality and hospitalisation, better uptake of peritoneal dialysis and earlier placement of arteriovenous fistulae for patients with chronic kidney disease who were referred early to a nephrologist. Differences in mortality and hospitalisation data between the two groups were not explained by differences in prevalence of comorbid disease or serum phosphate. However, early referral was associated with better preparation

Full Text available with Trip Pro

2014 Cochrane

7. Oral adsorbents for preventing or delaying the progression of chronic kidney disease. (PubMed)

Oral adsorbents for preventing or delaying the progression of chronic kidney disease. Chronic kidney disease (CKD) is a worldwide public health problem which is at high increased risk of cardiovascular disease (CVD) and renal failure. Deterioration of kidney function causes an increase in circulating toxins, which, in turn promotes the progression of CKD. Oral adsorbents with capacity to adsorb and remove substances including uraemic toxins from the intestine could be effective in minimising (...) Infrastructure (to May 2012); Wan Fang database (to May 2012).Randomised controlled trials (RCTs) and quasi-RCTs comparing any oral adsorbents for preventing or delaying the progression of CKD.Two authors independently assessed and extracted information. Information was collected on methods, participants, interventions and outcomes (incidence of end-stage kidney disease (ESKD), mortality, quality of life and adverse events). Results were expressed as risk ratios (RR) for dichotomous outcomes or as mean

Full Text available with Trip Pro

2014 Cochrane

8. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). (PubMed)

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney disease-mineral and bone disorder (CKD-MBD). This is an update of a review first published in 2011.The aim of this review was to assess the benefits and harms of phosphate binders for people (...) with CKD with particular reference to relevant biochemical end-points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal

2018 Cochrane

9. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). (PubMed)

Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular events. However, limited evidence is available regarding the use of aspirin in CKD patients to decrease cardiovascular risk and to slow renal disease progression.Prospective, multicenter, open-label randomized controlled trial.One (...) in the aspirin group. Aspirin significantly reduced the risk of coronary events (log-rank, 5.997; p = 0.014). Seventeen patients in the control group reached the renal outcome in comparison with 3 patients in the aspirin group. Aspirin treatment decreased renal disease progression in a model adjusted for age, baseline kidney function, and diabetes mellitus (HR, 0.272; 95% CI, 0.077-0.955; p = 0.043) but did not when adjusted for albuminuria. No differences were found in minor bleeding episodes between groups

2018 Cardiovascular Drugs and Therapy

10. Gout medication may slow progression of chronic kidney disease

these results are promising, they are based on low-quality trials. The low rate of side effects should be taken into account when considering these drugs as an option to slow the progression of kidney failure and prevent heart disease. Share your views on the research. Why was this study needed? Moderate to severe kidney disease affects 2.6 million people in England. It has a variety of causes including diabetes and inflammation. Management aims to slow progression through a variety of measures including (...) disease is a lifelong condition which is often progressive. Treatment of kidney disease is limited to prevention of deterioration by control of blood pressure and other risk factors. For end-stage disease dialysis or kidney transplant may be required. As the incidence of chronic kidney disease is increasing, finding new ways to slow progression is important. Some uric acid-lowering medications are cheap and relatively safe. These results should help inform shared decision making for people with high

2019 NIHR Dissemination Centre

11. Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD

Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD ________________________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 9 Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We suggest (...) creatinine throughout the EDIC study were also observed (0.89 vs 0.92 mg/dL (78.7 vs 8.13 µmol/L), P 250 mol/L) or dying from renal disease either between conventional ________________________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 3 of 9 and intensive therapy groups, or agents used in intensive therapy. Hypoglycaemic episodes were more common in patients receiving intensive therapy. A cohort of 3227

2013 KHA-CARI Guidelines

12. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial (PubMed)

Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folic acid therapy on renal outcomes has not been previously investigated in populations without folic acid fortification.To test whether treatment with enalapril and folic acid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) disease (CKD) among Chinese adults with hypertension.In this substudy of eligible China Stroke Primary Prevention Trial (CSPPT), 15 104 participants with an estimated glomerular filtration rate (eGFR) 30 mL/min/1.73 m2 or greater, including 1671 patients with CKD, were recruited from 20 communities in Jiangsu province in China.Participants were randomized to receive a single tablet daily containing 10 mg enalapril and 0.8 mg folic acid (n = 7545) or 10 mg enalapril alone (n = 7559).The primary outcome

Full Text available with Trip Pro

2016 EvidenceUpdates

13. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7

2017 National Guideline Clearinghouse (partial archive)

14. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

) is a nearly universal complication of progressive loss of kidney function. Biochemical abnormalities, vascular calcification, and bone fragility constitute the CKD-MBD syndrome, and each is consistently associated with increased risks for morbidity and mortality in large observational studies across the spectrum of CKD. x 1 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney (...) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) - American Journal of Kidney Diseases Email/Username: Password: Remember me Search Terms Search within Search Share

2017 National Kidney Foundation

15. Gout medication may slow progression of chronic kidney disease

these results are promising, they are based on low-quality trials. The low rate of side effects should be taken into account when considering these drugs as an option to slow the progression of kidney failure and prevent heart disease. Share your views on the research. Why was this study needed? Moderate to severe kidney disease affects 2.6 million people in England. It has a variety of causes including diabetes and inflammation. Management aims to slow progression through a variety of measures including (...) disease is a lifelong condition which is often progressive. Treatment of kidney disease is limited to prevention of deterioration by control of blood pressure and other risk factors. For end-stage disease dialysis or kidney transplant may be required. As the incidence of chronic kidney disease is increasing, finding new ways to slow progression is important. Some uric acid-lowering medications are cheap and relatively safe. These results should help inform shared decision making for people with high

2018 NIHR Dissemination Centre

16. [Aldosterone antagonists for preventing the progression of chronic kidney disease]. (PubMed)

[Aldosterone antagonists for preventing the progression of chronic kidney disease]. 27574006 2017 05 08 2018 11 13 1433-0563 55 10 2016 Oct Der Urologe. Ausg. A Urologe A [Aldosterone antagonists for preventing the progression of chronic kidney disease]. 1360-1363 Schmidt S S DGU-Hauptstadtbüro Berlin, Deutsche Gesellschaft für Urologie e.V., Kuno-Fischer-Str. 8, 14057, Berlin, Deutschland. schmidt@dgu.de. Spek A A Urologische Klinik, Klinikum der Universität München, Großhadern, Marchioninistr (...) . 15, 81377, München, Deutschland. ger Journal Article Randomized Controlled Trial Aldosteron-Antagonisten zur Prävention des Fortschreitens der chronischen Niereninsuffizienz. Germany Urologe A 1304110 0340-2592 0 Angiotensin Receptor Antagonists 0 Angiotensin-Converting Enzyme Inhibitors 0 Mineralocorticoid Receptor Antagonists IM Angiotensin Receptor Antagonists therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Humans Kidney Failure, Chronic diagnosis drug therapy

2017 Der Urologe. Ausg. A

17. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression. (PubMed)

Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression. Nuclear factor erythroid 2-related factor 2 (NRF2) is a critical transcription factor for the antioxidative stress response and it activates a variety of cytoprotective genes related to redox and detoxification. NRF2 activity is regulated by the oxidative-stress sensor molecule Kelch-like ECH-associated protein 1 (KEAP1) that induces proteasomal degradation of NRF2 through ubiquitinating NRF2 under unstressed conditions (...) . Because oxidative stress is a major pathogenic and aggravating factor for kidney diseases, the KEAP1-NRF2 system has been proposed to be a therapeutic target for renal protection.Oxidative-stress molecules, such as reactive oxygen species, accumulate in the kidneys of animal models for acute kidney injury (AKI), in which NRF2 is transiently and slightly activated. Genetic or pharmacological enhancement of NRF2 activity in the renal tubules significantly ameliorates damage related to AKI and prevents

Full Text available with Trip Pro

2017 American journal of nephrology

18. Daily Intake of Grape Powder Prevents the Progression of Kidney Disease in Obese Type 2 Diabetic ZSF1 Rats (PubMed)

Daily Intake of Grape Powder Prevents the Progression of Kidney Disease in Obese Type 2 Diabetic ZSF1 Rats Individuals living with metabolic syndrome (MetS) such as diabetes and obesity are at high risk for developing chronic kidney disease (CKD). This study investigated the beneficial effect of whole grape powder (WGP) diet on MetS-associated CKD. Obese diabetic ZSF1 rats, a kidney disease model with MetS, were fed WGP (5%, w/w) diet for six months. Kidney disease was determined using blood (...) of antioxidants (Dhcr24, Gstk1, Prdx2, Sod2, Gpx1 and Gpx4) and downregulation of Txnip (for ROS production) in the kidneys. Furthermore, addition of grape extract reduced H₂O₂-induced cell death of cultured podocytes. In conclusion, daily intake of WGP reduces the progression of kidney disease in obese diabetic rats, suggesting a protective function of antioxidant-rich grape diet against CKD in the setting of MetS.

Full Text available with Trip Pro

2017 Nutrients

19. Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic‐reperfusion injury (PubMed)

Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic‐reperfusion injury Acute kidney disease (AKI) leads to increased risk of progression to chronic kidney disease (CKD). Antithrombin III (ATIII) is a potent anticoagulant with anti-inflammatory properties, and we previously reported that insufficiencies of ATIII exacerbated renal ischaemia-reperfusion injury (IRI) in rats. In this study, we examined the characteristic of AKI-CKD transition in rats (...) with two distinct AKI models. Based on our observation, left IRI plus right nephrectomy (NX-IRI) was used to determine whether ATIII had therapeutic effects in preventing CKD progression after AKI. It was observed that NX-IRI resulted in significant functional and histological damage at 5 weeks after NX-IRI compared with sham rats, which was mitigated by ATIII administration. Besides, we noticed that ATIII administration significantly reduced NX-IRI-induced interstitial fibrosis. Consistently, renal

Full Text available with Trip Pro

2017 Journal of cellular and molecular medicine

20. Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease

Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease (NutriAKI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02831062 Recruitment Status : Unknown Verified July 2016 by Ravindra Mehta, University of California, San Diego. Recruitment

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>